UCL Technology Fund supports UCL Cancer Institute’s research into Covid-19 treatment
19 June 2020
The UCL Cancer Institute aims to use existing research to develop a treatment for Covid-19.
Led by Dr Martin Pule and Professor Kerry Chester, UCL Department of Oncology, the project will investigate using existing research into cancer treatments to help people with Covid-19. The aim is to create a unique ‘cocktail’ of recombinant antibodies capable of preventing the virus from entering cells and removing it from circulation.
Scientists will identify and clone antibodies from genetic material produced by white blood cells from recovered Covid-19 patients who have made effective antibodies to the virus.
The UCL Technology Fund, which is funding this research, is managed by AlbionVC in collaboration with UCL Business (UCLB), the university’s commercialisation company and part of UCL Innovation & Enterprise. The fund supports UCL in achieving the full potential of innovations that have prospects for outstanding societal impact.
Dr Celia Caulcott, Vice-Provost (Enterprise), said: “We’re delighted to be in the unique position of being able to open up the expertise of the UCL Cancer Institute researchers to pivot cancer antibody engineering know-how towards the challenge of Covid-19.”
Find out more about:
Photo credit: iStock.com/Koto Feja